ROS1 and non-small cell lung carcinoma: ROS1 resistance mutations were identified in 38% cases in the crizotinib-resistant biopsies, over one half of patients had unknown mechanisms of resistance to crizotinib based on gene sequencing alone.[7] Several driver gene mutations were reported after crizotinib resistance in ROS1 positive NSCLC.